Drug Profile
Betifisolimab - Transcenta Holding
Alternative Names: MSB-2311Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator MabSpace Biosciences
- Developer MabSpace Biosciences; Transcenta Holding
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Discontinued Haematological malignancies
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 24 Mar 2022 Discontinued - Phase-I for Haematological malignancies (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (Transcenta Holding pipeline, March 2022)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Haematological-malignancies(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV, Infusion)